First-in-class insomnia drug on the brink of approval nod

Osborne, Randy
July 2013
Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p492
Academic Journal
The article reports that an advisory committee of the U.S. Food and Drug Administration (FDA) has voted positively on the approval of suvorexant, Merck's first-in-class dual orexin receptor antagonist (DORA) for insomnia. It notes that zolpidem and other β-aminobutyric acid (GABA) agonists dominate today's insomnia market. Actelion Pharmaceuticals and GlaxoSmithKline are other firms pursuing DORA for insomnia. The FDA committee says DORAs are still associated with some safety issues.


Related Articles

  • Insomniacs get new mechanism sleep drug Belsomra. Sheridan, Cormac // Nature Biotechnology;Oct2014, Vol. 32 Issue 10, p968 

    The article reports on the drug approval of Merck & Co. Inc.'s Belsomra by the U.S. Food and Drug Administration (FDA) on August 13, 2014. The drug is a new class for trestment options available to insomnia sufferers. Belsomra is an orexin antagonist, which works by inhibiting the orexin...

  • FDA Seeks More Data on Actelion's Zavesca.  // Bioworld Week;3/15/2010, Vol. 18 Issue 11, p4 

    The article reports that U.S. Food and Drug Administration (FDA) issued a demand for preclinical and clinical information from Actelion Ltd. on Zavesca, a potential treatment for a rare neurodegenerative genetic disorder.

  • FDA Approval of Treximet Crowds Migraine Space. Hollingsworth, Catherine // BioWorld Today;4/17/2008, Vol. 19 Issue 75, p1 

    The article reports on the U.S. Food and Drug Administration approval for Treximet drug, jointly developed by Pozen Inc. and GlaxoSmithKline PLC, for the acute treatment of migraine attacks with or without aura in adults, in April 2008. Background on the drug, as well as results of clinical...

  • NEW RX. STEIN, JULIANNE // Drug Topics;Jan2014, Vol. 158 Issue 1, p78 

    The article discusses the approval of drugs from pharmaceutical companies by the U.S. Food and Drug Administration (FDA). GlaxoSmithKline has revealed approval of vilanterol and umeclidinium inhalation powder as combination of longacting muscarinic antagonist and a long-acting beta agonist...

  • GlaxoSmithKline: progress for Rotarix in key US market.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p24 

    The article reports that the biologics license application for Rotarix by GlaxoSmithKline has been accepted for review by the U.S. Food and Drugs Administration. This is welcome news for the drug maker as the vaccine, which received European Union approval in 2006, has the potential to become a...

  • Chain Pharmacy: REPORTER'S NOTEBOOK.  // Drug Store News;10/23/2006, Vol. 28 Issue 14, p14 

    The article reports on U.S. Food and Drug Administration drug approvals. A colorectal cancer drug Vectibix from Amgen Inc. has been approved for colon cancer treatments. FluLaval from GlaxoSmithKline is the FDA-approved vaccines to treat flu for winter. Lamictal has been approved for the fifth...

  • Pipeline.  // Medical Marketing & Media;Nov2006, Vol. 41 Issue 11, p10 

    The article reports developments related to drug approval issued by the U.S. Food and Drug Administration. Merck and Co. Inc. has won an approval for Zolinza, which is indicated for cutaneous manifestations in patients with cutaneous T-cell lymphoma. GlaxoSmithKline PLC was granted approval for...

  • Pipeline.  // Medical Marketing & Media;May2007, Vol. 42 Issue 5, p10 

    The article offers news briefs related to pharmaceutical industry in the U.S. The Food and Drug Administration (FDA) has approved the combination pill Janumet, which is for type two diabetes, of Merck & Co. Inc. GlaxoSmithKline has announced that the FDA has authorized its antibacterial Altabax...

  • Other Female Cancers Update.  // PharmaWatch: Cancer;Jul2006, Vol. 5 Issue 7, p8 

    The article provides update on the treatment for female cancers from various pharmaceutical industry in the U.S. The vaccine that prevents cervical cancer Gardasil of Merck & Co. Inc. has been approved by the Food and Drug Administration (FDA) to be given to women aged nine to 26. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics